This database is crucial for forensic laboratories around the world as it facilitates the quick identification of illicit substances. Compiled from both legal and illegal sources, it provides access to the latest novel psychoactive substances (NPS) such as variants of fentanyl, xylazine, various opioids, synthetic cannabinoids, and more. Wiley, one of the world’s largest scientific publishers, has announced the publication of the Mass Spectra of Designer Drugs for 2025.

This GC-MS database is updated annually and provides access to 36,360 spectra representing 27,500 unique chemical units, along with detailed information and chemical structures. This year’s update includes over 1,260 new spectra and over 780 unique compounds in key categories of interest.

“Forensic laboratories need up-to-date databases to stay ahead of emerging NPS trends. This resource is critical in the ongoing war on drugs,” said Graeme Whitley, Director, Data Science Solutions at Wiley.

The Mass Spectra of Designer Drugs database is compatible with most popular mass spectrometry data systems. In addition, it is available as a KnowItAll subscription, which integrates with Wiley’s KnowItAll spectral analysis software, which enables automated, non-targeted analysis including feature recognition, automatic unfolding, and library search with just one touch. It also includes tools to identify new compounds, such as drug classification models and a patented MS Adaptive Search Tool, which provides tremendous insight into structural possibilities when there is no exact match.

Further information:

Mass Spectra of Designer Drugs 2025 – Wiley Science Solutions

Read Also:

“Growing Database”: Wiley Introduces Updated AntiBase Library – MedLabPortal

Editor: X-Press Journalistenbüro GbR

Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.